Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company

Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches

Fineline Cube Nov 15, 2023

Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this...

Company Deals

Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research

Fineline Cube Nov 15, 2023

Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with...

Company Drug

EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation

Fineline Cube Nov 15, 2023

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...

Company Deals

PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank

Fineline Cube Nov 15, 2023

PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB...

Company Deals

Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes

Fineline Cube Nov 15, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to...

Policy / Regulatory

China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products

Fineline Cube Nov 15, 2023

The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement...

Company Medical Device

Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU

Fineline Cube Nov 15, 2023

China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received...

Company Deals

Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin

Fineline Cube Nov 15, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership...

Company Deals Digital Hospital

Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China

Fineline Cube Nov 15, 2023

Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into...

Company Drug

Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s

Fineline Cube Nov 15, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...

Company

CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments

Fineline Cube Nov 15, 2023

China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...

Company Deals

Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal

Fineline Cube Nov 14, 2023

China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...

Company Deals R&D

Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery

Fineline Cube Nov 14, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Company Deals

Autobio Diagnostics Expands Strategic Partnership with Guorun Medical Supply Chain Services

Fineline Cube Nov 14, 2023

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with Guorun Medical...

Company Digital

BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal

Fineline Cube Nov 14, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...

Company Drug

Bayer Withdraws Aliqopa FDA Filing Following Missed Phase III Endpoint

Fineline Cube Nov 14, 2023

Germany-based pharmaceutical major Bayer (ETR: BAYN) has announced its decision to withdraw the filing for...

Company Deals

Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics

Fineline Cube Nov 14, 2023

Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led...

Company Deals

AnchorDx Medical Partners with DiaCarta for Global Molecular Diagnostics Development

Fineline Cube Nov 14, 2023

AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered...

Company

Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan

Fineline Cube Nov 14, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical...

Company Deals

Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing

Fineline Cube Nov 14, 2023

Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens...

Posts pagination

1 … 495 496 497 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.